medigraphic.com

2001, Number 4

<< Back Next >>

Arch Cardiol Mex 2001; 71 (4)

Acute coronary syndromes without st elevation

Luciardi H, Muntaner J, Berman S, Serna F, Costantini C

Language: Spanish
References: 65
Page: 295-305
PDF size: 108.38 Kb.


ABSTRACT

The incidence of unstable angina and non-Q-wave myocardial infarction has increased dramatically. Risk of death and infarction is greatest in the first 6-8 weeks after admission. Risk stratification should be performed in patients with acute coronary syndromes at the earliest opportunity. The VANQWISH trial and TIMI-III B suggested that most patients do not benefit from routine, early invasive management. In the FRISC II trial, the rates of death/myocardial infarction at 6 months were 9.4% in patients treated with an early invasive strategy vs 12.1% with a more conservative approach. The previously reported superiority of the invasive strategy was also confirmed by the TACTICS-TIMI 18. The trial´s primary composite end point at 6 months was significantly reduced in the invasive group: 15.9% vs 19.4% of the conservative group. The early invasive strategy was more beneficial the higher the patient´s risk. We do not know whether we have reached the limits in terms of improving outcome with available strategies. What we do know is that all patients discharged following an acute coronary syndromes need to be treated aggressively in order to neutralize vulnerable atherosclerotic plaques and to manage cardiovascular risk factors.


REFERENCES

  1. Fuster V, Badimon L, Badimon J, Chesebro J: The pathogenesis of coronary artery disease and the acute coronary syndromes (Part I). N Engl J Med 1992; 326: 242-50.

  2. Fuster V, Badimon L, Badimon J, Chesebro J: The pathogenesis of coronary artery disease and the acute coronary syndromes (Part II). N Engl J Med 1992; 326: 310-8.

  3. Zaacks S, Liebson P, Calvin J, Parrillo J, Klein L: Unstable angina and non-Q wave myocardial infarction: Does the clinical diagnosis have therapeutic implications? J Am Coll Cardiol 1999; 33: 107-18.

  4. Ambrose J, Hjemdahl-Mouser C, Borrico S, Gorlin R, Fuster V: Angiographic demonstration of a common link between angina pectoris and non-Q wave myocardial infarction. Am J Cardiol 1988; 61: 244-247.

  5. Jeffrey A, Breall M, Allen J, Salomon N, Gersh B: Non-Q wave myocardial infarction: You cannot judge a “book” by its cover. ACC Current Journal Review 1998; (3): 15-18.

  6. ACC/AHA Task Force Report: Guidelines for the early management of patients with acute myocardial infarction. J Am Coll Cardiol 1988; 56: 249-92.

  7. ACC/AHA Task Force on practice guidelines (Committee on management of acute myocardial infarction) Guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996; 28: 1328-419.

  8. Stone P, Raabde D, Haffe A, for the MILIS Group. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988; 11: 453-63.

  9. Nicod P, Gilpin E, Dittrich H, Polikar R, Hjalmarseon A, Blacky R, Henning H, Ross J: Short and long-term clinical outcome after Q wave and non-Q wave myocardial infarction in a large patient population. Circulation 1989; 79: 528-36.

  10. Benhorin J, Moss A, Oakes D, Marcus F, Greenberg H, Dwyer E: The prognostic significance of first myocardial infarction type (Q wave vs non-Q wave) and Q wave location. J Am Coll Cardiol 1990; 15: 1201-7.

  11. Aguiire F, Younis L, Chaitman B, Ross A, McMahon R, Kern M, Berger P, Sopko G, Rogers W, Shaw L, Knatterud G, Braunwald E, for the TIMI-II investigators. Early and 1-year clinical outcome of patient evolving non-Q vs Q wave myocardial infarction after thrombolysis. Circulation 1995; 91: 2541-8.

  12. Goodman S, Califf R, Sgarbossa E, Barbegalata A: Mortality, morbidity resource use and quality of life following Q vs non-Q wave infarction following thrombolytic therapy: a GUSTO substudy (abstract). J Am Coll Cardiol 1997; 31: 490 A.

  13. Zareba W, Moss A, Raubertas R: Risk of subsequent cardiac events in stable convalescing patients after first non-Q wave and Q wave myocardial infarction: the limited role of non-invasive testing. Cor Artery Dis 1994; 5: 1009-18.

  14. Thanavaro S, Krone R, Kleiger R, Province M, Miller P, deMello V, Oliver C: In-hospital prognosis of patients with first nontransmural and transmural infarctions. Circulation 1980; 61: 29-33.

  15. Krone R, Friedman E, Thanavaro S, Miller J, Kleigfer R, Oliver C: Long-term prognosis after first Q wave (transmural) or non-Q wave (nontransmural) myocardial infarction. Analysis of 593 patients. Am J Cardiol 1983; 52: 234.

  16. Welty F, Mittleman M, Lewis S, Healy R, Shubrooks S, Muller J: Significance of location (anterior vs inferior) and type (Q wave vs non-Q wave) of acute myocardial infarction in patients undergoing percutaneous transluminal coronary angioplasty for postinfarction ischemia. Am J Cardiol 1995; 76: 431-5

  17. Phibbs B, Marcus F, Marriott H, Moss A, Spodick D: Q-wave versus non-Q wave myocardial infarction: A meaningless distinction. J Am Coll Cardiol 1999; 33 (2): 576-82.

  18. Lotan C, Jonas M, Rozenman Y: Comparison of early invasive and conservative treatment in patients with anterior wall non-Q wave acute myocardial infarction. Am J Cardiol 1995; 76: 330-6.

  19. Ghazzal Z, Chalasani P, Shen Y, Weintraub W: Long-term outcome of patients with non-Q wave myocardial infarction with and without revascularization. J Am Coll Cardiol 1998; 31: 14 A.

  20. The TIMI IIIB Trial. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave myocardial infarction. Results of the TIMI IIIB trial. Circulation 1994; 89: 1545-656.

  21. Anderson H, Cannon C, Stone P, Williams D, McCabe C, Knatterud G, Thompson B, Willerson J, Braunwald E, for the TIMI IIIB Investigators. One year results of the Thrombolysis in Myocardial Infarction (TIMI) III B clinical trial: a randomized comparison of tissue type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.

  22. Boden W, O’Rourke R, Crawford M, Blaustein A: Outcomes in patients with acute non-Q wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998; 338: 1785-92.

  23. Goy J-J. Contemporary approach to management of unstable angina. Lancet 1999: 354: 694-5.

  24. Madsen J, Grande P, Saunamaki K, for the DANAMI Study. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction. Circulation 1997; 96: 748-55.

  25. Lange R, Hills L: Use and Overuse of Angiography and Revascularization for Acute Coronary Syndromes. N Engl J Med 1998; 338: 1838-39.

  26. Théroux P, Fuster V: Acute coronary syndromes. Unstable angina and non-Q wave myocardial infarction. Circulation 1998, 97: 1195-1206.

  27. The OASIS Registry Investigators. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. Lancet 1998: 352: 507-14.

  28. Halon D, Flugelman M, Merdler A, Rennert H, Shahla J, Lewis B: Long-term (10 year) outcome in patients with unstable angina pectoris treated with by coronary balloon angioplasty. J Am Coll Cardiol 1998; 32: 1603-1609.

  29. FRISC II (FRagmin and Fast Revascularization during InStability in Coronary artery disease) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15.

  30. FRISC II (FRagmin and Fast Revascularization during InStability in Coronary artery disease) Investigators. Long term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 701-07.

  31. The PRISM-PLUS. (The Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488- 1497.

  32. The PRISM (The Platelet Receptor Inhibition in Ischemic Syndrome Management) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparina for unstable angina. N Engl J Med 1998; 338: 1498-1505.

  33. The PURSUIT. (The platelet glycoprotein IIb/IIIa unstable angina in receptor suppression using integrilin therapy) trial investigators. Inhibition of the platelet glycoprotein IIb/IIIa with epifibatide in patient with acute coronary syndromes without persisting ST segment elevation: a randomized placebo controlled clinical trial. N Engl J Med 1998; 339: 436-43

  34. Serruys P, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrick G, Emanuelsson H, Marco J, Materne P, for the BENESTENT Study Group. A comparison of ballon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.

  35. Cannon C, Weintraub W, Demopoulus L, Robertson D, Gormley G, Braunwald E, for the TACTICS-TIMI 18 Investigators. Invasive versus conservative strategies in unstable angina and non-Q wave myocardial infarction following treatment with tirofiban: rationale and study design of the International TACTICS-TIMI 18 Trial. Am J Cardiol 1998; 82: 731-736.

  36. Cannon C, Weintraub W, Demopoulus L for The TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87.

  37. Antman E, Cohen M, Bernink P: The TIMI Risk Score for Unstable Angina/Non-ST Elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-842.

  38. Fox K, Purcell H: Improving outcome in acute coronary syndromes - as good as it gets? Eur Heart J 1999; 20: 1533-1537.

  39. FRISC (FRagmin during InStability in Coronary artery disease) Study Group: Low molecular weight heparin during instability in coronary artery disease. Lancet 1996; 347: 561-568.

  40. Klein W, Buchwald A, Hillis S: Comparison of low molecular weight heparin with unfractioned heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 96: 61-68.

  41. Cohen M, Bigonzi F, Goldman S, for the ESSENCE Group. One year follow-up of the ESSENCE Trial (Enoxaparin versus Heparin in Unstable Angina and Non-Q wave Myocardial Infarction). J Am Coll Cardiol 1998; 31 (Suppl A): 79A.

  42. Verheught F: Hotline Sessions at the 20th European Congress of Cardiology. Eur Heart J 1998; 20: 7-10.

  43. Campbell R, Wallentin L, Verheugt F, Turpie A, Maseri A, Klein W, Cleland J, Bode C, Becker R, Anderson J, Bertrand M, Conti R: Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. Clin. Cardiol 1998; 21: 314-322.

  44. Metz B, White H, Granger C, Simes R, Armstrong P, Hirsh J, Fuster V, MacAuley C, Califf R, Topol E: Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO IIb trial. J Am Coll Cardiol 1998; 31: 1493-98.

  45. Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with suspected unstable angina or myocardial infarction without ST elevation: a randomized trial. Lancet 1999; 353: 429-438.

  46. The TIMI-9B Investigators. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) - 9B trial. Circulation 1996; 94: 911-921.

  47. Fox K: Implications of the OASIS-2 study and the results in the context of other trials. Am J Cardiol 1999; 84: 26M-31 M.

  48. The PARAGON investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin or both in unstable angina. Circulation 1998; 97: 2386-2395.

  49. The EPIC investigators. Ischemic complications of coronary angyoplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased. N Engl J Med 1994; 330: 956-961.

  50. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.

  51. The CAPTURE Investigators. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-1435.

  52. Cannon C, Mc Cabe C, Wilcox R: for the OPUS TIMI-16 Investigators. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-56.

  53. EXCITE (Evaluation of Oral Xemilofiban in Controlling Thrombotic Events) Trial Investigators. Long term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. N Engl J Med 2000; 342: 1316-24.

  54. The SYMPHONY Investigators. Comparison of Sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomized trial. Lancet 2000; 355: 337-45.

  55. Anand S: The Organization to Assess Strategies for Ischemic Síndromes (OASIS) Pilot Study. Evaluation of acute and long term therapies for patients with acute coronary syndromes without ST elevation. Am J Cardiol 1999; 84 (5A): 13-19.

  56. CURE Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme. Eur Heart J 2000; 21: 2033-2041.

  57. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(7): 494-502.

  58. Antman E: The search for replacement for Unfractionated Heparin. Circulation 2001; 103: 2310-14.

  59. Savonitto S, Ardissino D, Granger C: Prognostic value of the admission electrocardiogram in acute coronary syndromes. J Am Med Assoc 1999; 281: 707-713.

  60. McCullough P, O’Neill W, Graham M: A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy: results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) trial. J Am Coll Cardiol 1998; 32: 596-605.

  61. ACC/AHA guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnosis and Therapeutic Cardiovascular Procedures. Circulation 1990; 82: 664-707.

  62. Muntaner J, Luciardi H, Altman R: Ateroesclerosis: ¿Por qué una enfermedad inflamatoria? Rev Fed Arg Cardiol 1999; Vol.28(2): 210-216.

  63. Luciardi H, Muntaner J, Berman S, Rouviere J, Scazziota A, Altman R: Antiinflamatorios no esteroides en angina inestable. Estudio Nut Rev Fed Arg Cardiol 1999; Vol. 28 (3): 381-386.

  64. Morrow D, Antman E, Tanasijevic M: Cardiac troponin I for stratification of early outcomes and the efficacy of enoxaparin in unstable angina: a TIMI 11B substudy. J Am Coll Cardiol 2000; 36: 1812-7.

  65. Heeshen C, Hamm C, Goldman B, Deu A, Langenbrink L, White H: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet 1999; 354: 1757-62.




2020     |     www.medigraphic.com